Insulet Corporation $PODD Shares Sold by Symmetry Partners LLC

Symmetry Partners LLC lowered its position in shares of Insulet Corporation (NASDAQ:PODD) by 3.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,443 shares of the medical instruments supplier’s stock after selling 131 shares during the period. Symmetry Partners LLC’s holdings in Insulet were worth $1,082,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Zions Bancorporation National Association UT acquired a new position in Insulet in the 1st quarter valued at about $26,000. Larson Financial Group LLC boosted its holdings in Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares in the last quarter. SouthState Corp boosted its holdings in Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 76 shares in the last quarter. Kozak & Associates Inc. purchased a new stake in Insulet in the 2nd quarter valued at approximately $32,000. Finally, Ramirez Asset Management Inc. purchased a new stake in Insulet in the 1st quarter valued at approximately $53,000.

Analysts Set New Price Targets

Several brokerages have recently commented on PODD. Morgan Stanley reissued an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. Canaccord Genuity Group increased their price target on Insulet from $331.00 to $353.00 and gave the company a “buy” rating in a report on Friday, August 8th. Wells Fargo & Company lifted their price target on Insulet from $330.00 to $350.00 and gave the stock an “overweight” rating in a research note on Friday, August 8th. Oppenheimer lifted their price target on Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a research note on Monday, September 8th. Finally, Truist Financial began coverage on shares of Insulet in a report on Monday, June 16th. They issued a “buy” rating and a $365.00 target price on the stock. Sixteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $343.06.

Insider Activity

In other Insulet news, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Insulet Trading Down 1.7%

Shares of NASDAQ:PODD opened at $318.00 on Friday. The firm has a fifty day moving average of $319.01 and a two-hundred day moving average of $296.97. The firm has a market capitalization of $22.38 billion, a P/E ratio of 96.66, a price-to-earnings-growth ratio of 2.64 and a beta of 1.36. Insulet Corporation has a 12-month low of $225.37 and a 12-month high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same quarter last year, the business posted $0.55 EPS. The company’s revenue for the quarter was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts expect that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.